– Typewriter's site-specific, non-viral technology uses only LNP-delivered RNA to insert whole genes into the genome, to create safer, re-dosable, durable genetic medicines –

– Typewriter 的位点特异性、非病毒技术仅利用脂质纳米颗粒（LNP）递送的 RNA，将完整基因插入基因组，从而开发出更安全、可重复给药且持久的基因疗法 –

– Matthew Stanton, PhD, and Leanne Peiser, DPhil, appointed CEO and CSO, respectively; former Pfizer CSO Mikael Dolsten, MD, PhD, joins Typewriter board as independent director and the Fred Hutch's Stanley R. Riddell, MD, joins Typewriter Scientific Advisory Board –

– 马修·斯坦顿博士和莉安·佩瑟博士分别被任命为首席执行官和首席科学官；前辉瑞公司首席科学官米凯尔·多尔斯滕医学博士、哲学博士加入Typewriter董事会，担任独立董事；弗雷德·哈钦森癌症研究中心的斯坦利·R·里德尔医学博士加入Typewriter科学顾问委员会 –

CAMBRIDGE, Mass. and TOKYO

马萨诸塞州剑桥市和东京

,

，

Sept. 2, 2026

2026年9月2日

/PRNewswire/ -- Typewriter Therapeutics, Inc., a biotech company developing safe, durable and re-dosable genetic medicines with curative impact for patients with cancer, autoimmune diseases, and severe genetic diseases, today emerged from stealth with $56 million in Series A financing led by AN Venture Partners and RA Capital Management with participation from ANRI, Gemseki, and SBI US Gateway Fund.

/美通社/ -- Typewriter Therapeutics, Inc. 是一家生物科技公司，致力于开发安全、持久且可重复给药的基因药物，旨在为癌症、自身免疫性疾病和严重遗传性疾病患者带来治愈性疗效。该公司今日宣布结束隐身模式，并完成5600万美元的A轮融资。本轮融资由AN Venture Partners和RA Capital Management领投，ANRI、Gemseki以及SBI US Gateway Fund参投。

In addition, Typewriter announced the appointments of Matthew Stanton, PhD, as Chief Executive Officer, Leanne Peiser, DPhil, as Chief Scientific Officer, and Mikael Dolsten, MD, PhD, as a member of the company's board of directors..

此外，Typewriter宣布任命马修·斯坦顿（Matthew Stanton）博士为首席执行官，莱恩·佩瑟（Leanne Peiser）哲学博士为首席科学官，米凯尔·多尔斯滕（Mikael Dolsten）医学博士、哲学博士为公司董事会成员。

Typewriter's Target-Primed Reverse Transcription (TPRT) technology platform is built on the R2 retrotransposon, a natural gene-insertion system discovered by the company's academic co-founders. Typewriter's two-part, all-RNA therapy comprises a payload mRNA to make the R2 protein and a second RNA containing the therapeutic gene flanked by sequences to recruit the R2 protein.

Typewriter 公司的靶标启动逆转录（TPRT）技术平台基于 R2 逆转录转座子构建，这是一种由公司学术联合创始人发现的自然基因插入系统。Typewriter 的双组分全 RNA 疗法包括用于表达 R2 蛋白的有效载荷 mRNA，以及另一条包含治疗性基因且两侧带有招募 R2 蛋白序列的 RNA。

Inside the cell, the two assemble into an active complex that inserts the gene into the specific target site by TPRT. The R2 machinery then degrades along with the mRNA, leaving only the inserted gene at its intended location..

在细胞内，两者组装成一个活性复合物，通过靶向引物逆转录（TPRT）将基因插入到特定的靶位点。随后，R2机制与mRNA一同降解，仅在其预定位置留下插入的基因。

Typewriter's initial focus will be on two high-value indications with life-changing potential to patients: in vivo CAR T and genetic liver diseases. The company's first NHP studies are planned for late 2026.

Typewriter 的初步重点将放在两个对患者具有改变生活潜力的高价值适应症上：体内 CAR-T 疗法和遗传性肝病。公司计划于 2026 年末开展首次非人灵长类动物（NHP）研究。

'By inserting a durable, functioning gene into a safe-harbor site in T cells using lipid nanoparticle-delivered RNA, our technology is designed to create safer, re-dosable genetic medicines that are accessible to many more patients than current cumbersome and complex CAR T approaches,' said Matthew Stanton, PhD, Chief Executive Officer and Board Director of Typewriter Therapeutics.

“通过利用脂质纳米颗粒递送的RNA，将持久且功能正常的基因插入T细胞的安全港位点，我们的技术旨在打造更安全、可重复给药的基因药物，使更多患者能够受益，而目前的CAR-T疗法则繁琐且复杂。”Typewriter Therapeutics首席执行官兼董事会董事马修·斯坦顿博士表示。

'This financing enables us to build on the proof-of-concept we have established in humanized mouse models and establish our first in vivo CAR T development candidate.'.

“此次融资使我们能够在已建立的人源化小鼠模型概念验证基础上，推进并确立我们的首个体内CAR-T开发候选药物。”

Prior to Typewriter, Matthew Stanton was a Venture Partner at Raven, RA Capital's healthcare incubator. Before Raven, he spent seven years at Generation Bio, first as Chief Technology Officer and for the past five years as Chief Scientific Officer. Prior to Generation, he was Vice President and Head of Chemistry at Moderna Therapeutics, where his team identified proprietary lipid nanoparticles for vaccine development and helped to bring the first mRNA vaccines into clinical development..

在加入Typewriter之前，Matthew Stanton曾担任Raven（RA Capital旗下的医疗健康孵化器）的风险合伙人。在加入Raven之前，他在Generation Bio工作了七年，最初担任首席技术官，最近五年担任首席科学官。在加入Generation Bio之前，他曾担任Moderna Therapeutics的副总裁兼化学部门负责人，其团队为疫苗开发确定了专有的脂质纳米颗粒，并推动了首批mRNA疫苗进入临床开发阶段。

Newly appointed CSO Leanne Peiser brings to Typewriter more than 20 years of R&D leadership across biotech and pharma, with deep expertise in immunology, immunotherapy, and cellular therapy, including autologous, allogeneic, and in vivo CAR T for oncology and autoimmune diseases. Most recently, as Executive Director of Translational Research, Cellular Therapy at Bristol Myers Squibb (BMS), she served as a senior scientific lead for their CAR T portfolio across multiple indications..

新任首席科学官Leanne Peiser为Typewriter带来了超过20年的生物技术和制药研发领导经验，在免疫学、免疫疗法和细胞治疗领域拥有深厚的专业知识，包括用于肿瘤和自身免疫性疾病的自体、异体和体内CAR-T疗法。最近，她在百时美施贵宝（BMS）担任转化研究执行董事，负责细胞治疗领域，并作为其CAR-T产品组合的高级科学负责人，覆盖多个适应症。

'The mRNA vaccines proved to the world that RNA delivered by a lipid nanoparticle can become a medicine at global scale. Typewriter takes that breakthrough a decisive step further –using only RNA not to express a transient protein, but to write a durable therapeutic gene into a precise, safe location in the genome, without a virus,' said Mikael Dolsten, MD, PhD, independent board director at Typewriter Therapeutics and former Chief Scientific Officer and President of Worldwide Research & Development at Pfizer.

“mRNA疫苗向世界证明，通过脂质纳米颗粒递送的RNA可以成为全球规模的药物。Typewriter公司将这一突破性进展又向前迈出了决定性的一步——仅利用RNA，并非用于表达瞬时蛋白，而是将持久的治疗性基因写入基因组中精确且安全的位置，且无需使用病毒。”Typewriter Therapeutics公司独立董事、辉瑞公司前全球研发总裁兼首席科学官Mikael Dolsten医学博士、哲学博士表示。

'I am especially excited by what this means for in vivo CAR T. Engineering a patient's own T cells in vivo with an LNP-delivered RNA medicine could combine simpler administration with durable CAR expression and the ability to re-dose, potentially making cell therapy safer and accessible to far more patients than today's complex manufacturing allows. It is a privilege to join the board and help bring this platform to patients with cancer, autoimmune, and genetic diseases.'.

“我对这一进展对体内CAR-T疗法的意义感到尤为兴奋。通过脂质纳米颗粒（LNP）递送的RNA药物在患者体内对其自身T细胞进行工程化改造，可以将更简便的给药方式与持久的CAR表达及重复给药能力相结合，从而有望提高细胞疗法的安全性，并使更多患者能够受益于该疗法，突破当前复杂生产工艺的限制。能够加入董事会并帮助将这一平台应用于癌症、自身免疫性疾病和遗传性疾病患者的治疗，我深感荣幸。”

Typewriter is led by an experienced management team, including:

Typewriter 由一支经验丰富的管理团队领导，其中包括：

Matthew Stanton, PhD, Chief Executive Officer

马修·斯坦顿，博士，首席执行官

Leanne Peiser, DPhil, Chief Scientific Officer

莉安·佩瑟，哲学博士，首席科学官

Jun Zhou, PhD, Founder and Vice President, Discovery and Global Operations

周军，博士，创始人兼副总裁，负责发现与全球运营

Ari Friedland, PhD, Vice President, Research

阿里·弗里德兰博士，研究副总裁

Mayu Yoshikawa, PhD, President, Typewriter Japan

吉川真由，博士，Typewriter Japan 总裁

In addition to Matthew Stanton and Mikael Dolsten, Typewriter's board of directors includes board chair Ken Horne, Managing Partner, AN Venture Partners and Laura Tadvalkar, PhD, Managing Director at RA Capital.

除了马修·斯坦顿（Matthew Stanton）和米凯尔·多尔斯滕（Mikael Dolsten）之外，Typewriter 的董事会还包括董事会主席肯·霍恩（Ken Horne，AN Venture Partners 管理合伙人）以及劳拉·塔德瓦尔卡（Laura Tadvalkar）博士（RA Capital 董事总经理）。

Typewriter also announced that Stanley R. Riddell, MD, has joined as a member of its Scientific Advisory Board. Dr. Riddell is a member of the Translational Science and Therapeutics Division at Fred Hutchinson Cancer Center and Professor of Medicine at the University of Washington. He was the principal investigator on the first human trial of adoptively transferred therapeutic T cells, and his laboratory's CAR T work was licensed to Juno Therapeutics, which he co-founded and which is now part of Bristol Myers Squibb..

Typewriter 还宣布，斯坦利·R·里德尔（Stanley R. Riddell）医学博士已加入其科学顾问委员会。里德尔博士是弗雷德·哈钦森癌症中心转化科学与治疗学部的成员，也是华盛顿大学的医学教授。他是首例过继性治疗性 T 细胞人体试验的主要研究者，其实验室在 CAR-T 领域的工作已授权给朱诺治疗公司（Juno Therapeutics）；该公司由他联合创立，现隶属于百时美施贵宝（Bristol Myers Squibb）。

About Typewriter Therapeutics

关于打字机疗法公司

Typewriter Therapeutics is a start-up company that focuses on developing and commercializing RNA-based gene therapies for patients suffering from cancer, autoimmune, and severe genetic disorders. Typewriter's cutting-edge platform technology enables the targeted insertion of whole therapeutic genes to create safer, durable, and re-dosable medicines.

Typewriter Therapeutics 是一家初创公司，专注于为癌症、自身免疫性疾病和严重遗传病患者开发和商业化基于 RNA 的基因疗法。Typewriter 的前沿平台技术能够实现整个治疗基因的靶向插入，从而开发出更安全、持久且可重复给药的疗法。

Founded in February 2022, the company builds on the research of Professor Emeritus Haruhiko Fujiwara of the University of Tokyo on transposons. With research facilities in Tokyo and Cambridge, USA, Typewriter is committed to bringing Japan-originated technology to the global stage. For more information, visit .

该公司成立于2022年2月，依托东京大学名誉教授藤原春彦在转座子领域的研究成果。Typewriter在东京和美国剑桥设有研究机构，致力于将源自日本的技术推向全球舞台。欲了解更多信息，请访问。

www.typewritertx.com

www.typewritertx.com

.

。

SOURCE Typewriter Therapeutics, Inc.

来源：Typewriter Therapeutics, Inc.

21

二十一

%

百分之

more press release views with

更多新闻稿浏览量，通过

Request a Demo

申请演示